Abstract
AbstractAluminum-containing adjuvants have been used for nearly 100 years to enhance immune responses in billions of doses of vaccines. To date, only a few adjuvants have been approved for use in humans, among which aluminum-containing adjuvants are the only ones widely used. However, the medical need for potent and safe adjuvants is currently continuously increasing, especially those triggering cellular immune responses for cytotoxic T lymphocyte activation, which are urgently needed for the development of efficient virus and cancer vaccines. Manganese is an essential micronutrient required for diverse biological activities, but its functions in immunity remain undefined. We previously reported that Mn2+ is important in the host defense against cytosolic dsDNA by facilitating cGAS-STING activation and that Mn2+ alone directly activates cGAS independent of dsDNA, leading to an unconventional catalytic synthesis of 2′3′-cGAMP. Herein, we found that Mn2+ strongly promoted immune responses by facilitating antigen uptake, presentation, and germinal center formation via both cGAS-STING and NLRP3 activation. Accordingly, a colloidal manganese salt (Mn jelly, MnJ) was formulated to act not only as an immune potentiator but also as a delivery system to stimulate humoral and cellular immune responses, inducing antibody production and CD4+/CD8+ T-cell proliferation and activation by either intramuscular or intranasal immunization. When administered intranasally, MnJ also worked as a mucosal adjuvant, inducing high levels of secretory IgA. MnJ showed good adjuvant effects for all tested antigens, including T cell-dependent and T cell-independent antigens, such as bacterial capsular polysaccharides, thus indicating that it is a promising adjuvant candidate.
Funder
National Natural Science Foundation of China
Ministry of Science and Technology of the People’s Republic of China
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference75 articles.
1. Petrovsky, N. & Aguilar, J. C. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82, 488–496 (2004).
2. Apostolico Jde, S., Lunardelli, V. A., Coirada, F. C., Boscardin, S. B. & Rosa, D. S. Adjuvants: classification, modus operandi, and licensing. J. Immunol. Res. 2016, 1459394 (2016).
3. Pashine, A., Valiante, N. M. & Ulmer, J. B. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11, S63–S68 (2005).
4. Kaurav, M., Madan, J., Sudheesh, M. S. & Pandey, R. S. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage. Artif. Cells Nanomed. Biotechnol. 46, S818–S831 (2018).
5. McKee, A. S. & Marrack, P. Old and new adjuvants. Curr. Opin. Immunol. 47, 44–51 (2017).
Cited by
158 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献